Cell transplant study for transverse myelitis patients
Part of Brain & nervous system, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests if transplanting special cells into the spine is safe for people with transverse myelitis (a rare spinal cord inflammation) that has caused long-term weakness or trouble walking. It aims to see if these cells can help improve function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You had transverse myelitis diagnosed within the last 10 years, and your symptoms have been stable for at least 3 months
- You cannot walk without significant help or need a wheelchair
- You live within reasonable travel distance to the study center and have a caregiver who can help
- You have had up-to-date vaccinations for COVID-19, shingles, and flu
- You do not have other conditions like multiple sclerosis, certain autoimmune diseases, or active infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who have already received Q-Cells treatment. It does not test new treatments; instead, it checks on your health over a long time to see how you are doing.
This trial tests a cell transplant approach for people with a very severe spinal cord injury. It focuses first on safety and also looks for early signs the therapy may improve function.
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
This study tests a new treatment called Q-Cells®, which are special cells injected into the spinal cord to see if they can help slow ALS. It is for people with ALS who have a caregiver and are healthy enough to undergo the procedure.
This early-stage trial tests a new type of immune cell therapy (CAR T-cells) against several relapsed or hard-to-treat autoimmune diseases that affect the nervous system. The goal is to see if this treatment can safely calm the immune system and improve symptoms.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Hear when a new Transverse Myelitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.